196 related articles for article (PubMed ID: 18630351)
1. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
3. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of enzyme replacement therapy with idursulfase].
Gutiérrez-Solana LG
Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
[TBL] [Abstract][Full Text] [Related]
5. First treatment for Hunter syndrome.
FDA Consum; 2006; 40(6):5. PubMed ID: 17333554
[No Abstract] [Full Text] [Related]
6. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
7. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
8. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
[TBL] [Abstract][Full Text] [Related]
9. Idursulfase: I2S, iduronato-2-sulfatase.
Drugs R D; 2006; 7(4):254-8. PubMed ID: 16784250
[No Abstract] [Full Text] [Related]
10. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
[TBL] [Abstract][Full Text] [Related]
13. Treatment for Hunter syndrome approved.
FDA Consum; 2006; 40(5):4. PubMed ID: 17328099
[No Abstract] [Full Text] [Related]
14. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
15. Idursulfase for the treatment of mucopolysaccharidosis II.
Clarke LA
Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
[TBL] [Abstract][Full Text] [Related]
16. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
[TBL] [Abstract][Full Text] [Related]
19. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
[TBL] [Abstract][Full Text] [Related]
20. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK; Whiteman DA;
Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]